Vyvgart vs. IVIG: A Detailed Treatment Comparison

Vyvgart (efgartigimod) and IVIG attack autoimmune disease from opposite directions: Vyvgart strips harmful antibodies out of circulation, while IVIG floods the system with healthy antibodies that dial down the immune response. That fundamental difference shapes almost everything else about the two treatments, from how fast they kick in and how long relief lasts to what side effects show up and how convenient they are to use. Which one fits a given patient depends on the condition being treated, the urgency of the situation, and how the person’s body responds.

How Each Treatment Actually Works

Your body recycles its own IgG antibodies through a receptor called FcRn, which rescues them from being broken down and sends them back into circulation. That recycling system is the reason IgG antibodies last weeks in the bloodstream instead of days. In autoimmune conditions like myasthenia gravis, the immune system produces IgG antibodies that mistakenly attack the body’s own tissues. Vyvgart is an engineered fragment of an antibody designed to outcompete those harmful IgG molecules for FcRn binding, effectively blocking the recycling process so pathogenic antibodies get cleared faster than they normally would.¹ The result is a broad drop in total IgG levels, including the disease-causing antibodies.

IVIG works through a completely different and considerably messier set of mechanisms. It is pooled immunoglobulin collected from thousands of blood donors, so it contains a vast repertoire of antibodies that can influence the immune system in multiple ways simultaneously. IVIG can neutralize harmful cytokines, block activating receptors on immune cells, interfere with complement activation, and modulate T-cell and B-cell behavior. The fact that normal polyclonal IgG acts as both an effector molecule and a regulatory molecule is part of what makes IVIG effective across a surprisingly wide range of autoimmune and inflammatory conditions.² The trade-off is that this broad action also means the treatment is harder to predict and harder to target.

One useful way to think about it: Vyvgart is a precision subtraction, lowering the total amount of circulating IgG so that harmful antibodies lose their foothold. IVIG is an addition, flooding the system with competing signals that overwhelm the immune dysfunction. Both approaches reduce autoimmune damage, but through fundamentally different biology.

Evidence in Myasthenia Gravis

Generalized myasthenia gravis is where the comparison between these two treatments is sharpest, because it is the condition for which Vyvgart was first approved and where IVIG has the longest track record.

The pivotal trial for Vyvgart in myasthenia gravis, called ADAPT, enrolled patients who tested positive for acetylcholine receptor antibodies. In the first treatment cycle, roughly two-thirds of patients receiving Vyvgart met the threshold for meaningful improvement on a daily-living activities scale, compared with about three in ten on placebo.³ That response rate was strong enough to earn FDA approval.

IVIG, meanwhile, has decades of clinical use behind it. There is strong evidence supporting its use for short-term treatment during myasthenia gravis flares and crises, where it can reverse severe symptoms relatively quickly.⁴ For acute worsening, IVIG is backed by what researchers classify as the highest level of clinical evidence. Where the picture gets murkier is long-term maintenance: the controlled evidence for using IVIG indefinitely as a maintenance therapy in myasthenia gravis is limited, relying mostly on retrospective studies rather than rigorous randomized trials.⁵

Vyvgart was designed from the outset as a cyclical treatment, with patients receiving infusion cycles that can be repeated as needed. That positions it more naturally as a maintenance strategy. IVIG, by contrast, remains the go-to when you need to pull someone out of a crisis fast. Many neurologists now view these as complementary rather than interchangeable, with IVIG better suited for acute rescue and Vyvgart potentially better suited for ongoing management.

Evidence in CIDP

Chronic inflammatory demyelinating polyradiculoneuropathy, or CIDP, is the other major battlefield where these treatments compete. CIDP damages the myelin sheath around peripheral nerves, causing progressive weakness and sensory loss. IVIG has been a cornerstone treatment for years, and Vyvgart’s subcutaneous formulation recently showed strong results in a pivotal trial.

The ADHERE trial tested subcutaneous efgartigimod (Vyvgart’s under-the-skin version combined with an enzyme called hyaluronidase) in CIDP patients who had already shown they responded to existing therapy. Patients on efgartigimod had a substantially lower risk of relapse compared with placebo: about 28% relapsed versus roughly 54% on placebo.⁶ That translates to roughly a 60% reduction in the risk of relapse.

IVIG’s track record in CIDP is well established through multiple studies over a longer time frame. Long-term follow-up data show that IVIG treatment improves both motor and sensory symptoms over periods of two years, and it appears to prevent the ongoing nerve damage (axonal loss) that drives permanent disability in CIDP.⁷ On a widely used disability scale, IVIG produced a median improvement of one point, with benefits appearing particularly strong in women and in patients with relapsing disease patterns.⁸ Electrophysiology studies confirm that IVIG significantly reduces nerve conduction blocks and limits ongoing nerve fiber damage over time.⁹

For CIDP, the question is less about which treatment works and more about which one a given patient tolerates and can sustain. Many CIDP patients need treatment indefinitely, so the practical burden of each therapy matters enormously.

Side Effect Profiles

The side effect landscape differs meaningfully between these two treatments, and understanding the difference matters for anyone weighing them.

Vyvgart’s most commonly reported adverse events in clinical trials were headache and infections when given intravenously, and injection-site reactions when given subcutaneously.¹⁰ Post-marketing surveillance, which captures what happens in real-world use beyond clinical trials, has added some less expected signals. Urinary tract infection turned out to be the most frequently reported adverse event in the FDA’s post-marketing database, while sepsis, atrial fibrillation, and transient ischemic attack emerged as unexpected signals not prominently flagged during trials.¹¹ Because Vyvgart lowers total IgG levels, the infection risk makes biological sense: you have less circulating antibody to fight off pathogens while the drug is working.

IVIG carries a different set of concerns. Up to about 40% of intravenous infusions are associated with some kind of adverse event, though the vast majority are uncomfortable rather than dangerous. Headache is the single most common complaint.¹² Most side effects are immediate and mild, including fever and nausea alongside the headache.¹³ The rare but serious risks are the ones that demand attention: kidney damage, blood clots, heart rhythm problems, aseptic meningitis, hemolytic anemia (where the infused antibodies destroy the patient’s own red blood cells), and a lung injury syndrome called TRALI.¹⁴ These serious events are uncommon but can be life-threatening, particularly in older patients or those with pre-existing kidney disease or cardiovascular risk factors.

In practice, the choice often comes down to what a patient’s body tolerates. Some people sail through IVIG infusions without a problem; others dread them because of persistent headaches, fatigue, or nausea that wipe out a day or two after each treatment. Vyvgart’s lowered IgG brings a different kind of vigilance, especially around infection, but many patients find the side-effect experience milder overall.

Administration and Practical Burden

One of the biggest real-world differences between these treatments has nothing to do with efficacy data: it is the sheer logistics of receiving them.

IVIG infusions typically take several hours per session and often require a clinical setting, whether that is a hospital infusion center or a home health setup. Standard dosing courses can run three to five consecutive days for acute treatment, and maintenance schedules usually call for infusions every three to four weeks, each lasting hours. The infusion rate has to be carefully managed because going too fast increases the risk of side effects. For many patients, IVIG treatment becomes a significant time commitment that shapes their monthly schedule.

Vyvgart in its intravenous form takes about an hour per infusion, administered once weekly for four weeks per treatment cycle. The subcutaneous version is even faster, taking minutes rather than hours, and patients can potentially self-administer at home after training. Treatment cycles are repeated as needed based on symptom return, which for many patients means every few months rather than every few weeks. That cyclical approach can mean more time between treatment periods compared with the steady drum of monthly IVIG.

IVIG also carries a unique logistical vulnerability: it is a human blood product. Manufacturing immunoglobulin from pooled plasma takes seven to twelve months, compared with two to three months for synthetic biologic drugs like Vyvgart.¹⁵ The United States supplies roughly 70% of the world’s plasma, and shortages have occurred during disruptions like the COVID-19 pandemic.¹⁵ When supply tightens, patients who depend on IVIG can face delayed or rationed treatment. Vyvgart, as a manufactured biologic, does not depend on donor plasma and has a more predictable supply chain.

Vaccinations and Immune Protection

A natural worry with Vyvgart is whether lowering your IgG levels leaves you unable to respond to vaccines. After all, if the drug’s whole purpose is to reduce circulating antibodies, wouldn’t it also wipe out the antibodies your immune system builds after a flu shot or COVID booster?

Preclinical research suggests the concern is less serious than it sounds. In animal models testing both COVID-19 and influenza vaccines, treatment with an FcRn blocker (the same mechanism as Vyvgart) did lower virus-specific IgG levels as expected, but it did not reduce virus-specific IgM responses and did not impair the T-cell responses that provide deeper immune protection. When vaccinated animals were challenged with live virus, those treated with the FcRn blocker were equally protected as untreated vaccinated controls.¹⁶ The data line up with clinical observations in human patients: although IgG titers drop during treatment, the ability to generate new immune responses stays intact.

IVIG creates a different vaccination consideration. Because IVIG contains pre-formed antibodies from thousands of donors, it can interfere with certain live vaccines by neutralizing the weakened virus before the patient’s own immune system mounts a response. Guidelines typically recommend waiting several weeks to months after an IVIG infusion before receiving live vaccines like the MMR or varicella vaccines. Inactivated vaccines (like flu shots) can generally be given on schedule, though the immune response may be blunted.

Who Responds Best to Vyvgart

Not every patient with the same autoimmune condition responds equally to Vyvgart, and researchers are trying to figure out why. Early biomarker work points toward immune cell profiles as part of the answer. In a study of myasthenia gravis patients starting their first Vyvgart cycle, about 69% responded. Patients who did not respond tended to have higher baseline counts of natural killer (NK) cells, and lower levels of a signaling molecule called IL-12. A model combining just those two markers outperformed standard clinical measures at predicting who would benefit from treatment.¹⁷

This kind of work is still early stage, but it hints at a future where a blood test before starting Vyvgart could help predict whether you are likely to be in the two-thirds who respond or the one-third who do not. For IVIG, no comparable biomarker panel exists for predicting individual response, largely because its mechanism is so broad and multi-targeted that no single marker captures who will benefit.

Antibody subtype also matters. The ADAPT trial for Vyvgart specifically enrolled patients positive for acetylcholine receptor antibodies, and the strongest results were in that group. Patients with other antibody types, such as those targeting MuSK, are a biologically different population, and whether Vyvgart works as well for them is still being studied. IVIG, with its broader mechanism, has been used across antibody subtypes, though evidence quality varies.

Beyond Myasthenia Gravis and CIDP

Vyvgart’s mechanism, lowering IgG broadly by blocking its recycling, is potentially useful in any condition driven by pathogenic IgG antibodies. The drug’s developer has been running trials across a range of autoimmune diseases. Phase 3 studies are underway or have been completed in immune thrombocytopenia (where antibodies destroy platelets), while phase 2 and 3 trials are investigating the drug in pemphigus (a blistering skin disease), bullous pemphigoid (another autoimmune skin condition), and myositis (inflammatory muscle disease).¹⁸

IVIG already has a sprawling list of approved and off-label uses, including Kawasaki disease, Guillain-Barré syndrome, certain types of vasculitis, and many others. Its breadth of application reflects its broad mechanism: when you add a complex mixture of thousands of different antibodies, you get unpredictable but often helpful immunomodulatory effects across many conditions. In patients with Guillain-Barré syndrome, for example, pharmacokinetic modeling shows that IVIG produces a rapid initial rise in serum IgG followed by a gradual decline, with the rate of IgG clearance increasing in patients with more severe disease.¹⁹ That means sicker patients may clear the treatment faster, sometimes requiring dose adjustments or repeated courses.

Whether Vyvgart can eventually replace IVIG across multiple conditions remains to be seen. The appeal is obvious: a synthetic, supply-stable drug with a clean mechanism versus a blood-derived product with a complex supply chain and an unwieldy list of potential side effects. But IVIG’s multi-pronged action gives it a versatility that a targeted drug may not replicate in conditions where the pathology involves more than just IgG antibodies.

What Happens to IgG Over Time on Each Treatment

Understanding the kinetics of IgG on each treatment helps explain some of the clinical differences patients notice. Under normal conditions, IgG has a long half-life in the body, measured in weeks. In a study of patients with primary immunodeficiency receiving IVIG replacement, the average IgG half-life started around 43 days and shortened to about 33 days after repeated courses of treatment, as the body adjusted its clearance rate upward in response to the higher IgG load.²⁰ That means IVIG does not simply stack on top of existing IgG indefinitely; the body compensates by breaking IgG down faster.

Vyvgart works in the opposite direction. By blocking FcRn, it accelerates IgG degradation, producing a sharp drop in total IgG that reaches its lowest point about one to three weeks after a treatment cycle and then gradually recovers as the drug wears off. The cyclical dosing pattern is designed around this pharmacology: treat, let IgG drop, wait for symptoms to return, treat again. For most patients, the interval between cycles lands somewhere around two to three months, though it varies considerably from person to person. Some patients find their symptoms stay controlled for longer stretches, while others need more frequent cycles.

This cyclical nature is actually a practical advantage in one sense: during the recovery phase between Vyvgart cycles, IgG levels come back up, giving the immune system a window of more normal function. With continuous IVIG, the immune system is perpetually swimming in exogenous antibodies, which some researchers believe may contribute to the fatigue and general malaise that certain patients report between infusions.

Cost and Access Realities

Neither treatment is cheap, and the economics look different depending on where you live and what insurance you have. IVIG is one of the most expensive therapies in routine use across neurology and immunology, with annual costs that can reach into six figures depending on the dose and frequency. Vyvgart’s list price is also high, as is typical for targeted biologics. Cost-effectiveness analyses comparing the two are beginning to appear in the literature, though definitive conclusions remain elusive because they depend heavily on local pricing, treatment duration, and how broadly each drug’s benefits are measured.

Access is another dimension. IVIG is widely available and has been in use for decades, meaning clinicians are familiar with it and insurance pathways are well established. Vyvgart is newer and may require prior authorization or step therapy (demonstrating that you tried IVIG or another treatment first) before insurers will cover it. In countries outside the United States, access to Vyvgart lags further behind, while IVIG availability faces its own constraints tied to plasma supply and national self-sufficiency in blood products.

For patients caught between these treatments, the financial conversation is often as important as the clinical one. A treatment that is theoretically better may not be practically accessible, and a treatment that is accessible may not be the best fit for a particular patient’s disease pattern or lifestyle. Working through the specifics with a neurologist and a specialty pharmacy is usually the only way to figure out what is actually on the table.